long intergenic non-protein coding RNA 1756Genealiases: []
Q-omics provides the consensus-scored LINC01756 profile across patient tissues and cancer cell-line models. LINC01756 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01756 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, LINC01756 RNA expression shows 7,186 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, BRCA, and ESCA as cancer lineages where LINC01756 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01756 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01756 survival associations across molecular data types. LINC01756 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01756 RNA expression–survival associations across cancer types. High LINC01756 expression shows unfavorable associations in HNSC, THCA, CHOL, COAD and KIRP, but favorable associations in UCS. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01756 RNA expression.
This table summarizes LINC01756 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01756. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01756 shows lower tumor expression in PAAD and higher tumor expression in BRCA, LIHC, COAD, KIRC and STAD. The BRCA box plot shows higher LINC01756 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .019).
This table shows molecular features associated with LINC01756 in patient tissues and cancer cell lines. In patient samples, LINC01756 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
